Detalles de la búsqueda
1.
IgG1 responses following SARS-CoV-2 infection are polyclonal and highly personalized, whereby each donor and each clone displays a distinct pattern of cross-reactivity against SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-481778
2.
SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-458667
3.
Probing Affinity, Avidity, Anti-Cooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-448939
4.
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-222232
5.
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516125
6.
SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-466418
7.
The SARS-CoV-2 spike N-terminal domain engages 9-O-acetylated α2-8-linked sialic acids
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-507904
8.
Site-specific steric control of SARS-CoV-2 spike glycosylation
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-433764
9.
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430500
10.
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430866
11.
The impact of Spike mutations on SARS-CoV-2 neutralization
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-426849
12.
SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-255810
13.
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-233536
14.
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20120345
15.
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21264163
16.
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256092
17.
Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257797
18.
Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-512216
19.
Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-099507
20.
SARS-CoV-2 recruits a haem metabolite to evade antibody immunity
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21249203